{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:00:20Z","timestamp":1769065220026,"version":"3.49.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Ceftriaxone-induced encephalopathy is an exceptionally rare adverse effect of this commonly used cephalosporin and is generally observed in patients undergoing haemodialysis or suffering from severe renal failure. We present a case of a fit woman in her mid-80s with a normal renal function who developed severe fluctuating neurological symptoms (aphasia, loss of contact, chorea-like tongue movements) while being treated with ceftriaxone for a urinary tract infection with bacteraemia. The symptoms began on day 4 of treatment and an adverse drug reaction was suspected on day 7, after exhaustive investigations failed to reveal another cause. A complete recovery was observed 3\u2009days after discontinuing ceftriaxone. Our case highlights the need to consider the diagnosis of ceftriaxone encephalopathy, even if the traditional risk factors are lacking. In this article, we also provide a brief overview of the pathophysiology as well as a literature review concerning the subject.<\/jats:p>","DOI":"10.1136\/bcr-2023-256934","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:42Z","timestamp":1705017642000},"page":"e256934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftriaxone-induced encephalopathy in a patient with a normal renal function"],"prefix":"10.1136","volume":"17","author":[{"given":"Audrius","family":"Zarauskas","sequence":"first","affiliation":[{"name":"Internal Medicine, Hopital de Sion Centre Hospitalier du Valais Romand, Sion, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Internal Medicine, Hopital de Sion Centre Hospitalier du Valais Romand, Sion, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Neurology, H\u00f4pital de Sion Centre Hospitalier du Valais Romand, Sion, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"2025082801365936000_17.1.e256934.1","unstructured":"Sandoz Canada Inc . Ceftriaxone sodium for injection BP, product monograph, control# 255080 ; 2022."},{"key":"2025082801365936000_17.1.e256934.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00767-7"},{"key":"2025082801365936000_17.1.e256934.3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pediatrneurol.2003.07.006","article-title":"Cephalosporin-induced nonconvulsive status epilepticus in a uremic child","volume":"30","author":"Chedrawi","year":"2004","journal-title":"Pediatr Neurol"},{"key":"2025082801365936000_17.1.e256934.4","first-page":"72","article-title":"Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection","volume":"67","author":"Roncon-Albuquerque","year":"2009","journal-title":"Neth J Med"},{"key":"2025082801365936000_17.1.e256934.5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MAJ.0b013e3181ec063b","article-title":"Reversible choreoathetosis after the administration of ceftriaxone sodium in patients with end-stage renal disease","volume":"340","author":"Sato","year":"2010","journal-title":"Am J Med Sci"},{"key":"2025082801365936000_17.1.e256934.6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/0253-7613.91884","article-title":"Ceftriaxone-induced acute reversible encephalopathy in a patient with enteric fever","volume":"44","author":"Sharma","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"2025082801365936000_17.1.e256934.7","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3346\/jkms.2012.27.9.1120","article-title":"Ceftiaxone-induced neurotoxicity: case report, pharmacokinetic considerations, and literature review","volume":"27","author":"Kim","year":"2012","journal-title":"J Korean Med Sci"},{"key":"2025082801365936000_17.1.e256934.8","article-title":"Ceftriaxone-induced acute encephalopathy in a peritoneal dialysis patient","volume":"2014","author":"Safadi","year":"2014","journal-title":"Case Rep Nephrol"},{"key":"2025082801365936000_17.1.e256934.9","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2169\/internalmedicine.8774-16","article-title":"Ceftriaxone-induced neurotoxicity in a patient after pancreas-kidney transplantation","volume":"56","author":"Hagiya","year":"2017","journal-title":"Intern Med"},{"key":"2025082801365936000_17.1.e256934.10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ekir.2017.03.009","article-title":"Three cases of Hemodialysis patients receiving high-dose ceftriaxone: serum concentrations and its neurotoxicity","volume":"2","author":"Inoue","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2025082801365936000_17.1.e256934.11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000472148","article-title":"Choreoathetosis is a possible adverse event of a commonly used antibiotic","volume":"9","author":"Sathirapanya","year":"2017","journal-title":"Case Rep Neurol"},{"key":"2025082801365936000_17.1.e256934.12","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2017-134999"},{"key":"2025082801365936000_17.1.e256934.13","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2169\/internalmedicine.1785-18","article-title":"Encephalopathy induced by high plasma and cerebrospinal fluid ceftriaxone concentrations in a hemodialysis patient","volume":"58","author":"Suzuki","year":"2019","journal-title":"Intern Med"},{"key":"2025082801365936000_17.1.e256934.14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jocn.2019.05.035","article-title":"Cephalosporin-related neurotoxicity: metabolic encephalopathy or non-convulsive status epilepticus","volume":"67","author":"Triplett","year":"2019","journal-title":"J Clin Neurosci"},{"key":"2025082801365936000_17.1.e256934.15","article-title":"Reversible choreoathetosis in a patient with end-stage renal disease from administration of ceftriaxone","volume":"11","author":"Tan","year":"2019","journal-title":"Cureus"},{"key":"2025082801365936000_17.1.e256934.16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jiac.2019.10.005","article-title":"Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: a case report","volume":"26","author":"Yokoyama","year":"2020","journal-title":"J Infect Chemother"},{"key":"2025082801365936000_17.1.e256934.17","article-title":"Ceftriaxone-induced encephalopathy: a pharmacokinetic approach","volume":"8","author":"Jadot","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"2025082801365936000_17.1.e256934.18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijid.2022.01.023","article-title":"Ceftriaxone-associated encephalopathy in a patient with high levels of ceftriaxone in blood and cerebrospinal fluid","volume":"116","author":"Nishioka","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025082801365936000_17.1.e256934.19","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1111\/hdi.13018","article-title":"Two cases of ceftriaxone-induced encephalopathy treated by hemoperfusion in hemodialysis patients","volume":"26","author":"Onogi","year":"2022","journal-title":"Hemodial Int"},{"key":"2025082801365936000_17.1.e256934.20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ijid.2022.07.036","article-title":"Ceftriaxone-induced encephalopathy in a patient with a solitary kidney","volume":"122","author":"Futagi","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025082801365936000_17.1.e256934.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01581","article-title":"Encephalopathy induced by high levels of ceftriaxone in the blood and cerebrospinal fluid","volume":"29","author":"Minamii","year":"2022","journal-title":"IDCases"},{"key":"2025082801365936000_17.1.e256934.22","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10050540","article-title":"Serious neurological adverse events of ceftriaxone","volume":"10","author":"Lacroix","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025082801365936000_17.1.e256934.23","unstructured":"World Health Organization . WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva; 2018."},{"key":"2025082801365936000_17.1.e256934.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136220","article-title":"Hyperammonemia in urinary tract infections","volume":"10","author":"Kenzaka","year":"2015","journal-title":"PLoS One"},{"key":"2025082801365936000_17.1.e256934.25","article-title":"Hyperammonemic encephalopathy secondary to urinary tract infection","volume":"14","author":"Gorantla","year":"2022","journal-title":"Cureus"},{"key":"2025082801365936000_17.1.e256934.26","doi-asserted-by":"crossref","DOI":"10.25259\/SNI_483_2022","article-title":"Ceftriaxone-induced encephalopathy in a patient with multicentric glioma","volume":"13","author":"Anto","year":"2022","journal-title":"Surg Neurol Int"},{"key":"2025082801365936000_17.1.e256934.27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ebcr.2016.04.005","article-title":"Nonconvulsive status epilepticus cases arising in connection with cephalosporins","volume":"6","author":"Bora","year":"2016","journal-title":"Epilepsy Behav Case Rep"},{"key":"2025082801365936000_17.1.e256934.28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s11096-022-01406-7","article-title":"Analysis of the frequency of ceftriaxone-induced encephalopathy using the Japanese adverse drug event report database","volume":"44","author":"Yamada","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"2025082801365936000_17.1.e256934.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.232"},{"key":"2025082801365936000_17.1.e256934.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0704(05)70367-5"},{"key":"2025082801365936000_17.1.e256934.31","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L307"},{"key":"2025082801365936000_17.1.e256934.32","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00007-10"},{"key":"2025082801365936000_17.1.e256934.33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0002-9343(85)90262-1","article-title":"Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime","volume":"79","author":"Norrby","year":"1985","journal-title":"Am J Med"},{"key":"2025082801365936000_17.1.e256934.34","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu110"},{"key":"2025082801365936000_17.1.e256934.35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.5.816"},{"key":"2025082801365936000_17.1.e256934.36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1518"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:37:12Z","timestamp":1756370232000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bcr-2023-256934"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256934","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}